Embecta Corp. (EMBC)
NASDAQ: EMBCHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EMBC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $341.09M
- P/E (TTM)
- 4.10
- Forward P/E
- 3.42
- EPS (TTM)
- $1.47
- Dividend yield
- 7.64% ($0.46)
- Ex-dividend date
- Aug 27, 2026
- 52-week range
- 2.77 – 14.78
- Day range
- 5.90 – 6.40
- Volume / Avg
- 862.80K / 1.01M
- Beta
- —
- Shares outstanding
- 56.66M
- Next earnings
- Nov 24, 2026
52-week range
EMBC stock today
Shares of Embecta (EMBC) finished lower on Nov 20 at $6.02, a drop of 2.75% or $0.17 per share, versus the S&P 500's 3.70% decline. Shares are 59.3% below their 52-week high of $14.78, set on Nov 21, 2025 and 117.3% above the 52-week low of $2.77, in the middle of the past year's range. EMBC is down 49.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 58.7%.
At 4.1x trailing earnings, Embecta trades below the peer-group median of 32.6x. Its forward P/E of 3.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Nov 24 before the market opens; analysts expect EPS of $0.31. Embecta pays an annual dividend of $0.46 per share, a 7.64% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Embecta
Company profileEmbecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Devdatt Kurdikar Ph.D.
- Headquarters
- Parsippany, NJ
- Employees
- 1,850
- Website
- embecta.com
Financial highlights
Full financialsIn fiscal 2025, Embecta generated $1.08 billion in revenue, down 3.8% from fiscal 2024, its first annual decline since 2023. Net income was $95.4 million (+21.8% year over year), for a net margin of 8.8% versus a median of 19.8% in the prior 5 years. Gross margin was 62.6% (down from 65.5%) and operating margin 22.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.08B | $1.12B | $1.12B | $1.13B | $1.17B |
| Growth | -3.80% | +0.21% | -0.77% | -3.07% | +7.35% |
| Net income | $95.40M | $78.30M | $70.40M | $223.60M | $414.80M |
| EPS (diluted) | $1.62 | $1.34 | $1.22 | $3.89 | $7.28 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$4.00-33.55%
- Strong buy 0
- Buy 0
- Hold 3
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 24, 2026
- EPS estimate
- $0.31
- Last reported (Q3 2026)
- Aug 7, 2026
- EPS actual vs est.
- $0.36 vs —
Dividends
Dividend history- Annual dividend
- $0.46
- Dividend yield
- 7.64%
- Last payment
- $0.01
- Ex-dividend date
- Aug 27, 2026
EMBC news
All EMBC newsEmbecta peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BWAYBrainsWay Ltd. ADR | 8.48 | -2.86% | $341.35M | vs EMBC |
| CERSCerus Corporation | 1.85 | -2.63% | $373.62M | vs EMBC |
| MOBIMobia Medical Inc. | 11.85 | -0.08% | $394.50M | vs EMBC |
| INFUInfuSystems Holdings Inc. | 14.35 | +2.06% | $287.48M | vs EMBC |
| TMCITreace Medical Concepts Inc. | 4.31 | -0.92% | $282.56M | vs EMBC |
| NPCENeuropace Inc. | 7.95 | -2.33% | $273.89M | vs EMBC |
| SIShoulder Innovations Inc. | 20.15 | -0.79% | $421.58M | vs EMBC |
| SSIISS Innovations International Inc. | 1.27 | -0.78% | $254.86M | vs EMBC |
Indexes, lists and sector
Embecta stock FAQ
What is Embecta's stock price today?
EMBC last traded at $6.02 as of Nov 20, 4:00 PM EST, down 2.75% on the day. Prices are delayed at least 15 minutes.
Does Embecta pay a dividend?
Yes. Embecta pays $0.46 per share annually, a 7.64% yield. The most recent dividend of $0.01 had an ex-dividend date of Aug 27, 2026.
When is Embecta's next earnings date?
Embecta is expected to report earnings on Tuesday, November 24, 2026. Analysts expect EPS of $0.31.
What is EMBC's P/E ratio?
EMBC trades at a trailing P/E ratio of 4.10 and a forward P/E of 3.42, compared with a median of 32.6 for its closest peers.
Who is Embecta's CEO?
Mr. Devdatt Kurdikar Ph.D. is the chief executive officer of Embecta Corp., which has about 1,850 employees.
What is the EMBC 52-week high?
The 52-week high for EMBC is $14.78 and the 52-week low is $2.77. The stock is currently 59.3% below its high.